NCT02752113View on ClinicalTrials.gov

Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

November 7, 2018

Study Completion Date

May 31, 2019

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Empagliflozin and Linagliptin

Empagliflozin and Linagliptin

DRUG

Metformin and Insulin sc

Metformin and Insulin sc

Trial Locations (1)

91054

Clinical Research Center, Dept of Nephrology and Hypertenison, University of Erlangen/Nürnberg, Erlangen

All Listed Sponsors
collaborator

University of Erlangen-Nürnberg Medical School

OTHER

lead

Institut für Pharmakologie und Präventive Medizin

NETWORK

NCT02752113 - Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes | Biotech Hunter | Biotech Hunter